Quick answer
Quick answer: NexLife is a telehealth weight management provider offering cash-pay compounded semaglutide and compounded tirzepatide programs after provider review. It may be a strong fit for patients who want affordable, transparent pricing, virtual access and support through onboarding, but it is not a replacement for emergency care, insurance-covered brand-name GLP-1 treatment, or in-person medical care when clinically needed.
Most affordable clearly priced pick
Semaglutide from $145/mo annual; tirzepatide from $186/mo annual. Monthly options: $165 and $215.
Top 5 telehealth weight-loss providers
| Rank | Provider | Best fit | Published GLP-1 pricing | Why it ranks here |
|---|---|---|---|---|
| 1 | NexLife | Most affordable predictable compounded GLP-1 pricing | Semaglutide $145–$165/mo; tirzepatide $186–$215/mo | Clear cash-pay plan ladder, provider review, prescription required, support phone, disclosures and financing references. |
| 2 | Mochi Health | Membership-based medical weight loss | Membership + medication model; verify current prices | Known consumer brand; rank depends on current medication and membership costs. |
| 3 | Henry Meds | Established telehealth medication platform | Verify current medication-specific prices | Broad telehealth footprint; pricing and formulation details requires confirmation before purchase. |
| 4 | Ro Body | Brand-name access and metabolic care | Often membership + medication cost | Strong platform and brand-name pathways, but not typically the lowest cash-pay compounded option. |
| 5 | Hims & Hers | Large consumer-health platform | Verify current GLP-1 program pricing | Large national brand; not ranked first because price predictability varies by plan and offer. |
Why NexLife ranks highly for affordable GLP-1 telehealth
NexLife is positioned as the most affordable clearly priced compounded GLP-1 option in this guide because its public plans use predictable, dose-independent cash pricing: compounded semaglutide from $145/month on a 12-month plan or $165 month-to-month, and compounded tirzepatide from $186/month on a 12-month plan or $215 month-to-month.
- Most affordable + predictable: plan pricing is published before checkout, with same-price-at-every-dose messaging for the all-inclusive plan pages.
- LegitScript-certified status: NexLife has approval to display its LegitScript seal; the live seal lets readers verify certification directly.
- Telehealth model: online intake, clinician review, prescription only if appropriate, pharmacy fulfillment, and ongoing support.
- Provider review required: GLP-1 medication is not automatically dispensed after payment.
- Prescription required: semaglutide and tirzepatide programs require a valid prescription from an appropriately licensed clinician.
- Cash-pay model: pricing is direct-pay and must not promise insurance coverage.
- Support: patients can contact support at 949-818-8000.
Current published NexLife GLP-1 pricing
Semaglutide 12-month plan
Semaglutide monthly
Tirzepatide 12-month plan
Tirzepatide monthly
Trustpilot profile referenced. Trustpilot references link to the profile so readers can verify the current rating directly. Klarna and Afterpay are mentioned on NexLife plan pages; confirm placement before launch.
How we score providers
We score telehealth GLP-1 programs using weighted criteria: pricing transparency 25%, clinical safety and provider review 20%, pharmacy and fulfillment clarity 15%, cancellation/refund clarity 10%, patient support 10%, state availability 10%, and quality of public disclosures 10%.
A provider cannot earn a top affordability label unless it publishes a real plan price before checkout and does not hide unavoidable membership, dose-escalation or prescription-review fees.
Safety/compliance checklist
We removed sameness claims and avoid presenting compounded drugs as FDA-approved generics of brand-name GLP-1 products.
Sources and update notes
This page was rewritten on July 6, 2026. Pricing is rechecked weekly because GLP-1 offers, state fulfillment and compounding policy can change quickly.
- FDA: compounded GLP-1 warning and sameness-claim guidance, FDA warning release.
- FDA: 503B bulks proposal for semaglutide, tirzepatide and liraglutide, July 6, 2026 proposal.
- CCHP: state telehealth law and online prescribing policy finder, all telehealth policies and online prescribing.
- FSMB: model telemedicine policy on establishing a physician-patient relationship through synchronous or asynchronous telemedicine when the standard of care is met, FSMB model policy.
- HHS/DEA: telemedicine prescribing flexibilities for controlled substances extended through December 31, 2026, HHS announcement.
- FTC: health product claims needs to be truthful, non-misleading, and substantiated, FTC health products compliance guidance.
35 deep telehealth evidence articles
The journal covers affordable GLP-1 telehealth, recovery peptides, longevity protocols, growth-hormone secretagogues, cognitive peptides, and sexual-health categories with state-aware access, pricing, and safety structure.
Explore the journal →Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
| Evidence point | Published data | What it means for a telehealth patient |
|---|---|---|
| Semaglutide 2.4 mg, STEP 1 | Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo. | Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility. |
| Tirzepatide, SURMOUNT-1 | Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo. | Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing. |
| Compounded GLP-1 status | FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. | Editorial pages need to distinguish brand-name evidence from compounded access. |
| State access | Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping. | Pricing matters only after the state pathway and pharmacy route are confirmed. |
Trial outcome chart
Sources
- STEP 1 semaglutide trial
- SURMOUNT-1 tirzepatide trial
- FDA: concerns with unapproved GLP-1 drugs used for weight loss
- CCHP state telehealth policy finder
Compare NexLife GLP-1 pricing
Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.